Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:category |
gptkb:C
not recommended |
| gptkbp:clinical_trial |
Phase III
studied in various populations compared to placebo compared to oral antipsychotics |
| gptkbp:clinical_use |
long-term treatment of schizophrenia
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to paliperidone |
| gptkbp:dosage_form |
suspension for injection
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP2 D6 inhibitors CYP3 A4 inhibitors |
| gptkbp:duration |
long-term
|
| gptkbp:effective_date |
2015-06-17
|
| gptkbp:formulation |
long-acting injectable
extended-release injectable suspension |
| gptkbp:frequency |
once every three months
|
| https://www.w3.org/2000/01/rdf-schema#label |
Invega Trinza
|
| gptkbp:indication |
schizophrenia maintenance treatment
|
| gptkbp:ingredients |
gptkb:paliperidone
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
gptkb:weight
renal function extrapyramidal symptoms blood glucose lipid levels |
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
dopamine D2 receptor antagonist
serotonin 5-HT2 A receptor antagonist |
| gptkbp:patient_population |
adults
adolescents |
| gptkbp:pharmacokinetics |
long half-life
steady-state achieved after 4 doses |
| gptkbp:provides_guidance_on |
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:American_Psychiatric_Association |
| gptkbp:regulatory_compliance |
FDA approved
EMA approved Health Canada approved |
| gptkbp:related_to |
gptkb:Invega_Sustenna
gptkb:paliperidone_palmitate |
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:service_frequency |
every three months
|
| gptkbp:side_effect |
seizures
drowsiness cardiovascular events weight gain increased cholesterol hyperglycemia extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia prolactin elevation |
| gptkbp:storage |
refrigerated
|
| gptkbp:treatment |
individualized
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
treatment of schizophrenia
|
| gptkbp:website |
deltoid muscle
gluteal muscle |
| gptkbp:bfsParent |
gptkb:Paliperidone
|
| gptkbp:bfsLayer |
6
|